Compare PAR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | CAPR |
|---|---|---|
| Founded | 1968 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 699.1M | 584.9M |
| IPO Year | 1995 | 2011 |
| Metric | PAR | CAPR |
|---|---|---|
| Price | $14.39 | $8.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $25.31 | ★ $27.00 |
| AVG Volume (30 Days) | 823.3K | ★ 2.4M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $455,547,000.00 | N/A |
| Revenue This Year | $14.20 | N/A |
| Revenue Next Year | $9.92 | $1.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.16 | N/A |
| 52 Week Low | $11.59 | $2.96 |
| 52 Week High | $40.54 | $40.37 |
| Indicator | PAR | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 30.20 | 50.70 |
| Support Level | $13.85 | $8.18 |
| Resistance Level | $14.37 | $9.79 |
| Average True Range (ATR) | 0.73 | 0.52 |
| MACD | -0.23 | 0.15 |
| Stochastic Oscillator | 14.59 | 45.95 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). Its product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.